Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway

BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Koleini, Navid, Nickel, Barbara E., Wang, Jie, Roveimiab, Zeinab, Fandrich, Robert R., Kirshenbaum, Lorrie A., Cattini, Peter A., Kardami, Elissavet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675643/
https://www.ncbi.nlm.nih.gov/pubmed/29152091
http://dx.doi.org/10.18632/oncotarget.20558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675643/
https://www.ncbi.nlm.nih.gov/pubmed/29152091
http://dx.doi.org/10.18632/oncotarget.20558

Ejemplares similares